The Innovative Medicines Initiative (IMI) was launched in 2008 as a large-scale public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). With a total budget of €2 billion, the IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavors between large pharmaceutica...

Obtaining data without the intervention of a health care provider represents an opportunity to expand understanding of the safety of medications used in difficult-to-study situations, like the first trimester of pregnancy when women may not present for medical care. While it is widely agreed that personal data, and in particular medical data, needs to be protected from unauthorized use, data pr...

BACKGROUND The United Nations Millennium Development Goals galvanized global efforts to alleviate suffering of the world's poorest people through unprecedented public-private partnerships. Donor aid agencies have demonstrably saved millions of lives that might otherwise have been lost to disease through increased access to quality-assured vaccines and medicines. Yet, the introduction of these h...

The authors discuss procurement and provision of pharmaceutical products from the perspective of supply management in the public health sector, focusing on two main aspects: quality and cost. The article analyzes issues to be considered by buyers when evaluating drug quality, especially formulation stability, bioequivalence, and the role of generics. Also discussed are factors involving costs a...

The aim of this paper is to propose new organizational factors that might explain the differences in the extent and the speed of IT adoption. With this in mind, we carried out an analysis of 16 cases in the pharmaceutical distribution sector in Spain. The results indicate that there are certain intangible assets that favour the introduction and development of IT. Among these are a frank and flu...

BACKGROUND Pharmaceuticals are an integral component of health care systems worldwide, thus, regulatory weaknesses in governance of the pharmaceutical system negatively impact health outcomes especially in developing countries 1. Nigeria is one of a number of countries whose pharmaceutical system has been impacted by corruption and has struggled to curtail the production and trafficking of subs...

The paper provides an overview of current situation of the global pharmaceutical industry, with focus placed on the EU pharmaceutical market, including also the Romanian pharmaceutical market evolution synthetized into a SWOT analysis. As main goal the paper identifies several financial performance influence factors at the level of a number of companies from pharmaceutical sector, in order to g...

Eco friendly pharmaceutical packaging materials are the safe materials for environment which enclose pharmaceutical product in any of the dosage forms. They may be derived from natural resources, like starches, proteins etc. that inflict little or nearly no harm on the environment and the environment dependent species. This review highlight the eco friendly materials, their classification, uses...

The greater consciousness awakened in recent years on healthy and organic has led to increase “natural” products demand worldwide. The quality and high content on bioactive compounds have consolidated their penetration in cosmetic and food market, showing great potential within the pharmaceutical sector too. For this reason, food, cosmetic and pharmaceutical sectors have been forced to develop ...

The aim of this article is to present the development of the pharmaceutical industry in Syria using national and international public data sources. At the end of the 80ies, the pharmaceutical industry in Syria was very poor, covering 6% of the national needs. In less than 20 years, with the government support in terms of legal frame and strategic political engagement, the Syrian pharmaceutical ...